https://www.pharmaceutical-technology.com/news/epi
Post# of 36568
(Total Views: 339)
Posted On: 03/06/2020 6:13:45 PM
https://www.pharmaceutical-technology.com/new...9-vaccine/
Maybe no need to go to China - These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.
——-
In a separate development, Generex Biotechnology entered into a contract with EpiVax to leverage computational tools for identifying epitopes that can produce peptide vaccines against Covid-19.
Generex will also use its NuGenerex Immuno-Oncology Ii-Key technology.
EpiVax has detected multiple ‘hotspots’ in the amino acid sequences of coronavirus proteins.
Generex will now use epitopes predicted by EpiVax to generate a series of synthetic amino acid peptides that can imitate the virus’ epitopes. These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.
The blood samples are expected to contain immune cells and antibodies that will recognise the peptides, proteins and nucleic acids of the virus.
With blood sample testing, the company aims to validate if the predicted sequences will be suitable vaccine peptides.
Last month, Generex signed a contract with four companies in China for the development of an Ii-Key Peptide-based Covid-19 vaccine.
Maybe no need to go to China - These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.
——-
In a separate development, Generex Biotechnology entered into a contract with EpiVax to leverage computational tools for identifying epitopes that can produce peptide vaccines against Covid-19.
Generex will also use its NuGenerex Immuno-Oncology Ii-Key technology.
EpiVax has detected multiple ‘hotspots’ in the amino acid sequences of coronavirus proteins.
Generex will now use epitopes predicted by EpiVax to generate a series of synthetic amino acid peptides that can imitate the virus’ epitopes. These peptides will be sent to China for testing with blood samples of coronavirus patients who have recovered.
The blood samples are expected to contain immune cells and antibodies that will recognise the peptides, proteins and nucleic acids of the virus.
With blood sample testing, the company aims to validate if the predicted sequences will be suitable vaccine peptides.
Last month, Generex signed a contract with four companies in China for the development of an Ii-Key Peptide-based Covid-19 vaccine.
(3)
(0)